Alpha thalassemia is a genetic disorder called a hemoglobinopathy, or an inherited type of anemia. People who have alpha thalassemia make red blood cells that are not able to carry oxygen as well throughout the body, which can lead to anemia. This chronic anemia can include pale skin, fatigue, and weakness. In more severe cases, people with alpha thalassemia can also develop jaundice (yellowing of the eyes and skin), heart defects, and an enlarged liver and spleen (called hepatosplenomegaly).
Alpha thalassemia is more common in people of African, Southeast Asian, Chinese, Middle Eastern, and Mediterranean ancestries.
We have over 20,000 different genes in the body. These genes are like instruction manuals for how to build a protein, and each protein has an important function that helps to keep our body working how it should. The HBA1 and HBA2 genes make a protein called alpha-globin. Two of the alpha-globin proteins combine with two other proteins called beta-globins (which are made by the HBB gene) to make a normal red blood cell.
Most people have four copies of the genes that make the alpha-globin protein: two copies of the HBA1 gene (one from each parent), and two copies of the HBA2 gene (one from each parent). Having all four copies of these genes is symbolized by writing αα/αα. Whether or not someone has alpha thalassemia depends on how many working copies of the alpha-globin gene they have (if someone has a missing or nonworking alpha-globin gene, it is most frequently caused by a deletion):
Alpha thalassemia is inherited in a complex autosomal recessive inheritance pattern, and potential outcomes depend on the parent’s specific test results (how many copies of the alpha globin gene do the parents have on each of their chromosomes).
Prenatal testing and/or pre-implantation genetic testing options are available for couples who are identified to be at an increased chance to have a baby with alpha thalassemia.
How common alpha thalassemia is depends on the part of the world someone’s family is from. People whose families are from Northern Europe and North America have about a 1 in 1,000,000 chance to have alpha thalassemia. Approximately 4-20 out of every 1000 people whose families are from the Middle East, Southeast Asia, and certain Mediterranean countries have hemoglobin H disease. Exact numbers for how common alpha thalassemia is may not be completely accurate, as many people can have mild or no symptoms and may not even know that they have it.
Medical management for alpha thalassemia depends on the severity of symptoms that the person is experiencing. Because people who are silent carriers or those who have alpha thalassemia trait most frequently do not have any health symptoms related to this, no treatment is necessary.
Treatment for hemoglobin H disease may include taking folic acid supplements, blood transfusions (as needed), removal of iron (called iron chelation therapy) due to iron overload, and surgical removal of the spleen (splenectomy). Rarely, a bone marrow transplant (also called a stem cell transplant) may aid in the survival of a child with hemoglobin Bart syndrome. Bone marrow transplants carry many risks, so they are generally only considered in the most severe cases of alpha thalassemia.
Click here to learn more about scheduling a genetic counseling appointment for pregnancy-related questions.
Click here to learn more about scheduling a genetic counseling appointment for infertility or preconception questions.
Click here to learn more about scheduling a genetic counseling appointment for questions about pediatric or adult genetic conditions.